Ipatasertib - Genentech

Drug Profile

Ipatasertib - Genentech

Alternative Names: GCD 0068; GDC-0068; RG-7440

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Array BioPharma
  • Developer Chugai Pharmaceutical; Genentech; Roche Farma; SOLTI Breast Cancer Research Group
  • Class Antineoplastics; Heterocyclic bicyclo compounds; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer; Prostate cancer
  • Phase II Gastrointestinal cancer
  • Phase I Solid tumours

Most Recent Events

  • 09 Nov 2017 Genentech initiates enrolment in a phase I trial in Liver failure in USA (NCT03341884)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in France (PO)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top